bullish hammer reversal.., page-122

Surges...

"I would not expect results to come early as the estimated window for the announcement was already brought up forward from early next year, so it seems unlikely to surprise again within this window in an industry which usually runs late."

Very good point on the ANP managed ATL1103 trials.

Of course, the concurrent cancer trials may or may not be packages up with these...and of course corporate activity can come at any moment.

Then there is the Afandin agreement due to be sorted in the next month or so, and as always, ATL1102 that could surprise.

Left of field developments can always surprise...imagine if one of the big three on the register were to increase their positions...or indeed, a new substantial holder were to appear.

Not much on the news front from ANP this year...nor recently (which I think is the reason most missed the lows...but plenty expected in the next few months.

Cheers!